Skip to main content
SpringerLink
Log in

A relook at gastroenteropancreatic neuroendocrine tumours as per 2019 WHO classification—A tertiary centre experience

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Introduction

Neuroendocrine neoplasm of GIT (gastrointestinal tract) and pancreas is heterogenous with variable clinical features and disease outcomes. Despite multiple attempts of risk stratification by grading and staging, some have unpredictable clinical courses. Well-differentiated grade 3 neuroendocrine tumour (G3NET) is a recent subcategory introduced in the 2019 WHO classification based on morphology, molecular profile and prognosis distinguishing it from neuroendocrine carcinoma(NEC). This study aimed at describing the spectrum of NENs encountered in a tertiary centre with focus on reclassifying previously reported G3 tumours into G3 NET and NEC and comparing the survival between them.

Methodology

This is an 8-year retrospective study of all gastro-entero-pancreatic neuroendocrine neoplasms reclassified according to the 2019 WHO classification based on morphology and Ki-67 index with analysis of the survival rates between the categories. Minimum follow-up period was 20 months.

Results

Eighty-six patients with NENs of gastro-entero-pancreas were included, with median age group of 40–60 years (age range 9 to 79 years) and male:female ratio of 1.7:1. The tumour grade correlated with the TNM staging and most of the syndromic NETs were low grade. Eleven percent of the tumours were reclassified as well-differentiated G3NETs. The survival of G3 NETs was higher than NEC.

Conclusion

Grading of NEN is vital for therapeutic decisions and for prognostication. Currently, morphology is the key to recognise the well-differentiated G3 NETs, but can be subject to interobserver variability. Molecular surrogates may play a role in accurately identifying these entities, the validity of which is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kim JY, Hong SM (2016) Recent updates on neuroendocrine tumors from the gastrointestinal and pancreatobiliary tracts. Arch Pathol Lab Med 140:437–448. https://doi.org/10.5858/arpa.2015-0314-RA

    Article  CAS  PubMed  Google Scholar 

  2. Lokuhetty D, White V, Watanabe R, Cree I (2018) WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer

  3. Basturk O, Yang Z, Tang LH et al (2015) The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 39:683–690. https://doi.org/10.1097/pas.0000000000000408

    Article  PubMed  PubMed Central  Google Scholar 

  4. Tang LH, Basturk O, Sue JJ, Klimstra DS (2016) A practical approach to the classification of WHO grade 3 (G3) well differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol 40:1192. https://doi.org/10.1097/pas.0000000000000662

    Article  PubMed  PubMed Central  Google Scholar 

  5. Park JK, Paik WH, Lee K et al (2017) DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors. Oncotarget 8:49796. https://doi.org/10.18632/oncotarget.17964

  6. Ali AS, Grönberg M, Federspiel B et al (2017) Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. PLoS ONE 12:e0187667. https://doi.org/10.1371/journal.pone.0187667

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zhang MY, Du He SZ (2020) Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: differences in basic biology and treatment. World J Gastrointest Oncol 12:705. https://doi.org/10.4251/wjgo.v12.i7.705

    Article  PubMed  PubMed Central  Google Scholar 

  8. Sorbye H, Strosberg J, Baudin E et al (2014) Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 120:2814–2823. https://doi.org/10.1002/cncr.28721

    Article  CAS  PubMed  Google Scholar 

  9. Wang H, Ding D, Qin T et al (2022) Prognostic validity of the American joint committee on cancer eighth edition staging system for well-differentiated pancreatic neuroendocrine tumors. HPB 24:681–690. https://doi.org/10.1016/j.hpb.2021.10.017

    Article  CAS  PubMed  Google Scholar 

  10. Ahmed M (2020) Gastrointestinal neuroendocrine tumors in 2020. World J Gastrointest Oncol. 12(8):791. https://doi.org/10.4251/2Fwjgo.v12.i8.791

    Article  PubMed  PubMed Central  Google Scholar 

  11. Parra-Medina R, Moreno-Lucero P, Jimenez-Moreno J et al (2019) Neuroendocrine neoplasms of gastrointestinal tract and secondary primary synchronous tumors: a systematic review of case reports. Casualty or causality? PLoS One 14:e0216647. https://doi.org/10.1371/journal.pone.0216647

  12. Amarapurkar DN, Juneja MP, Patel ND et al (2010) A retrospective clinico-pathological analysis of neuroendocrine tumors of the gastrointestinal tract. Trop Gastroenterol 31:101–104

    CAS  PubMed  Google Scholar 

  13. Oronsky B, Ma PC, Morgensztern D, Carter CA (2017) Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia 19:991–1002. https://doi.org/10.1016/j.neo.2017.09.002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Faggiano A, Ramundo V, Circelli L, Colao A (2013) Hereditary neuroendocrine tumor syndromes. Hot Topics in endocrine and endocrine-related diseases, InTech 8:1–26. https://doi.org/10.5772/53841

    Article  CAS  Google Scholar 

  15. Conemans EB, Brosens LA, Raicu-Ionita GM et al (2017) Prognostic value of WHO grade in pancreatic neuro-endocrine tumors in multiple endocrine neoplasia type 1: results from the DutchMEN1 Study Group. Pancreatology 17:766–772. https://doi.org/10.1016/j.pan.2017.07.196

    Article  PubMed  Google Scholar 

  16. Cavalcanti MS, Gönen M, Klimstra DS (2016) The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications. Int J Endocr Oncol 3:203–219. https://doi.org/10.2217/ije-2016-0006

    Article  PubMed  PubMed Central  Google Scholar 

  17. Yang M, Zeng L, Ke NW et al (2020) World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution. BMC Cancer 1–11. https://doi.org/10.1186/s12885-020-07356-5

    Article  Google Scholar 

  18. Rindi G, Klimstra DS, Abedi-Ardekani B et al (2018) A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 31:1770–1786. https://doi.org/10.1038/s41379-018-0110-y

    Article  PubMed  PubMed Central  Google Scholar 

  19. Rindi G, Klersy C, Albarello L et al (2018) Competitive testing of the WHO 2010 versus the WHO 2017 grading of pancreatic neuroendocrine neoplasms: data from a large international cohort study. Neuroendocrinology 107:375–386. https://doi.org/10.1159/000494355

    Article  CAS  PubMed  Google Scholar 

  20. Shi H, Chen L, Meng L et al (2020) The role of Ki-67 index cut-off of 55% and differentiation in redefining NET and NEC for grade 3 gastrointestinal neuroendocrine neoplasms. J Gastroint Surg 24:2302–2305. https://doi.org/10.1007/s11605-020-04651-1

    Article  Google Scholar 

  21. Lithgow K, Venkataraman H, Hughes S et al (2021) Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort. Sci Rep 11:1–8. https://doi.org/10.1038/s41598-021-97247-x

    Article  CAS  Google Scholar 

  22. Briest F, Berg E, Grass I et al (2015) FOXM1: a novel drug target in gastroenteropancreatic neuroendocrine tumors. Oncotarget 6:8185. https://doi.org/10.18632/oncotarget.3600

  23. Cavalcanti E, Armentano R, Valentini AM et al (2017) Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading. Cell Death Dis 8:e3004–e3004. https://doi.org/10.1038/cddis.2017.401

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. GI and Liver Pathology, Amrita Institute of Medical Sciences, Kochi, Kerala, India

    Divya Achutha Ail

  2. Department of Pathology, Yenepoya Medical College, Mangalore, India

    Divya Achutha Ail

  3. Department of Pathology, Amrita Institute of Medical Sciences, Kochi, Kerala, India

    Roopa Rachel Paulose

Authors
  1. Divya Achutha Ail
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roopa Rachel Paulose
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: Divya Achutha Ail, Roopa Rachel Paulose. Data preparation/acquisition: Divay Achutha Ail. Methodology: Divya Achutha Ail, Roopa Rachel Paulose. Formal analysis and investigation: Divya Achutha Ail, Roopa Rachel Paulose. Writing—original draft preparation: Divya Achutha Ail. Writing—review and editing: Roopa Rachel Paulose. Supervision: Roopa Rachel Paulose.

Corresponding author

Correspondence to Roopa Rachel Paulose.

Ethics declarations

Ethical approval

Compliant.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ail, D.A., Paulose, R.R. A relook at gastroenteropancreatic neuroendocrine tumours as per 2019 WHO classification—A tertiary centre experience. Ir J Med Sci 192, 2065–2070 (2023). https://doi.org/10.1007/s11845-022-03217-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-022-03217-1

Keywords

Search

Navigation